Immunic (NASDAQ:IMUX) Receives Buy Rating from B. Riley

B. Riley reissued their buy rating on shares of Immunic (NASDAQ:IMUX) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock, down from their previous price objective of $6.00.

Several other research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Wednesday, April 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of Immunic in a report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Immunic has a consensus rating of “Buy” and an average target price of $13.00.

Immunic Stock Down 0.3%

IMUX opened at $0.92 on Friday. The firm has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.07. Immunic has a 52 week low of $0.83 and a 52 week high of $2.11. The company has a market capitalization of $87.92 million, a PE ratio of -0.75 and a beta of 1.73.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). As a group, sell-side analysts expect that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Focus Partners Wealth lifted its holdings in shares of Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after acquiring an additional 415,104 shares during the last quarter. Aberdeen Group plc purchased a new stake in Immunic in the 1st quarter worth about $1,155,000. 683 Capital Management LLC raised its position in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after purchasing an additional 200,000 shares during the period. Millennium Management LLC raised its position in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after purchasing an additional 479,846 shares during the period. Finally, Renaissance Technologies LLC raised its position in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.